We are leveraging our proprietary DELSCAPE platform to design and develop a pipeline of wholly owned, oral, small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas.

In collaboration with Sanofi, we are also developing a therapeutic candidate for immuno-oncology indications.